The upcoming days Lifecare will be productive and important for Lifecare in in Berlin where two presentations will be held at the prestigious conference ATTD. The company will also attend the steering committee of the FORGETDIABETES consortium.
Vis børsmeldingen
In the next days, Lifecare will participate at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) in Berlin. The company’s CSO, Prof. Dr. Dr. Andreas Pfützner, is invited to give two presentations at the conference.
CSO Prof. Pfützner will give a presentation about the successful miniaturization of Lifecare’s proprietary osmotic-pressure based glucose sensor for continuous intra peritoneal and subcutaneous glucose monitoring by means of nanotechnology. Lifecare’s CSO will also explain how this technology has been developed with successful results without compromising sensitivity or functionality.
In addition to the presentation about the Sencell, Prof. Dr. Dr. Pfützner will present Lifecare’s “Dynamic CGM interference testing method” as an E-poster.
FORGETDIABETES STEERING COMMITTEE
Lifecare is part of the prestigious EU funded research project FORGETDIABETES, where the company in cooperation with German, Italian and French academic institutions aim to develop an implantable artificial pancreas. Today, Lifecare is attending the project steering committee for discussions of progress and to coordinate the upcoming preclinical tests of the prototype artificial pancreas.
Lifecares primary tasks in the project is to develop the sensing element – an “implantable intra peritoneal sensor”, as well as an in-vitro test system for dynamic interference testing of glucose sensors, through Lifecares wholly owned subsidiary Lifecare Laboratory. In 2020 the European Commission granted the project funding of 3,9 million EUR under the Horizon 2020 program.
Last autumn EU’s Innovation Radar analyzed four key inventions in the project and concluded that two Lifecare-innovations are considered as key-inventions – the implantable intra peritoneal sensor and the in-vitro test system for dynamic interference testing of glucose sensors – is considered as “MARKET READY”.
Furthermore, based on signals from the Innovation Radar analyze, Lifecare’s inventions has been categorized in terms of disruptive potential based on the novel indicator system “Market Creation Potential Indicator” (MCPI) developed by the European Commission’s Joint Research Centre.
Lifecares inventions have been categorized with a “HIGH” market potential, the second highest category placing both Lifecare inventions among the top 14 % of all EU-funded innovations.
Further information Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40
This stock exchange announcement was published by Joacim Holter, CEO at Lifecare AS, on 22.2.23 at 08:15 CET.
This is Lifecare:
Lifecare is a Bergen-based technology company developing a miniaturized implantable long-term sensor for correct and continuous monitoring of blood sugar in people with diabetes. The Company’s patented technology also has the potential for use in various biomarkers. Lifecare AS is listed on Euronext Growth (LIFE).
Kilde
